International audienceThe constant heavy chain (CH1) domain affects antibody affinity and fine specificity, challenging the paradigm that only variable regions contribute to antigen binding. To investigate the role of the CH1 domain, we constructed IgA2 from the broadly neutralizing anti-HIV-1 2F5 IgG1, and compared 2F5 IgA2 and IgG binding affinity and functional activities. We found that 2F5 IgA2 bound to the gp41 membrane proximal external region with higher affinity than IgG1. Functionally, compared with IgG1, 2F5 IgA2 more efficiently blocked HIV-1 transcytosis across epithelial cells and CD4(+) cell infection by R5 HIV-1. The 2F5 IgG1 and IgA2 acted synergistically to fully block HIV-1 transfer from Langerhans to autologous CD4(+) T c...
Anti-human immunodeficiency virus type 1 (HIV-1) antibodies whose binding to gp120 is enhanced by CD...
The protective efficacy of human immunodeficiency virus-1 (HIV-1) antibodies (Abs) remains mostly co...
Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection...
International audienceThe constant heavy chain (CH1) domain affects antibody affinity and fine speci...
International audienceThe antibody molecule comprises a variable domain conferring antigen specifici...
<div><p>The broadly neutralizing HIV-1 antibody 2F5 recognizes an epitope in the gp41 membrane proxi...
The broadly neutralizing HIV-1 antibody 2F5 recognizes an epitope in the gp41 membrane proximal exte...
Background: Anti-HIV immunoconjugates targeted to the HIV envelope protein may be used to eradicate ...
Background: HIV-specific IgA is present in HIV-exposed uninfected individuals (EU) and neutralizes p...
HIV vaccine efforts tend to focus on the induction of IgG neutralizing antibodies. In part, this may...
The conserved HIV-1 site of coreceptor binding is protected from antibody-directed neutralization by...
International audienceAIDS is mainly a sexually transmitted disease, and accordingly, mucosal tissue...
Anti-HIV immunoconjugates targeted to the HIV envelope protein may be used to eradicate the latent r...
We have analyzed a panel of eight murine monoclonal antibodies (MAbs) that depend on the V2 domain f...
Antibodies that mediate killing of HIV-infected cells through antibody-dependent cellular cytotoxici...
Anti-human immunodeficiency virus type 1 (HIV-1) antibodies whose binding to gp120 is enhanced by CD...
The protective efficacy of human immunodeficiency virus-1 (HIV-1) antibodies (Abs) remains mostly co...
Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection...
International audienceThe constant heavy chain (CH1) domain affects antibody affinity and fine speci...
International audienceThe antibody molecule comprises a variable domain conferring antigen specifici...
<div><p>The broadly neutralizing HIV-1 antibody 2F5 recognizes an epitope in the gp41 membrane proxi...
The broadly neutralizing HIV-1 antibody 2F5 recognizes an epitope in the gp41 membrane proximal exte...
Background: Anti-HIV immunoconjugates targeted to the HIV envelope protein may be used to eradicate ...
Background: HIV-specific IgA is present in HIV-exposed uninfected individuals (EU) and neutralizes p...
HIV vaccine efforts tend to focus on the induction of IgG neutralizing antibodies. In part, this may...
The conserved HIV-1 site of coreceptor binding is protected from antibody-directed neutralization by...
International audienceAIDS is mainly a sexually transmitted disease, and accordingly, mucosal tissue...
Anti-HIV immunoconjugates targeted to the HIV envelope protein may be used to eradicate the latent r...
We have analyzed a panel of eight murine monoclonal antibodies (MAbs) that depend on the V2 domain f...
Antibodies that mediate killing of HIV-infected cells through antibody-dependent cellular cytotoxici...
Anti-human immunodeficiency virus type 1 (HIV-1) antibodies whose binding to gp120 is enhanced by CD...
The protective efficacy of human immunodeficiency virus-1 (HIV-1) antibodies (Abs) remains mostly co...
Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection...